◆ Salatino M, Girotti M, Rabinovich GA. Preview: “Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer”

◆ Option and Exclusive License Agreement with STCube, Inc. and ALPS Biotech Co., Ltd., covering the MDA16-085 technology titled “Dual Function Antibodies Specific To Glycosylated PD-L1 And Methods Of Use Thereof.”

In this study, we identified a TNBC-specific glycosylation event on PD-L1 essential for its interaction with PD-1 and subsequent suppression of T cell activities. We isolated a glycosylation-specific antibody that can efficiently internalize PD-L1 for endocytosis and generated an antibody-drug conjugate (ADC) against glycosylated PD-L1, which induces potent anti-tumor activities in TNBC models in vitro and in vivo. Our findings open a new direction to target glycosylation of co-inhibitory ligand/receptor as a therapeutic strategy.